ArticleAnnals of lymphoma2021
Epidemiology of Marginal Zone Lymphoma.
Article in Annals of lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Pulmonary amyloidosis, gastric MALT lymphoma, and multiple sclerosis in a patient with Sjögren's disease: a case report and review of the literature.Rheumatology international · 2026Pooled it
- Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.Blood advances · 2024Pooled it
- IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.Haematologica · 2024Trial
- Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.Blood advances · 2023Trial
- Concurrent presentation of distinct extranodal and splenic marginal zone lymphomas.Journal of hematopathology · 2026Article
- Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision-Making.European journal of haematology · 2026Review
- Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.Clinical drug investigation · 2026Article
- Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries.Future oncology (London, England) · 2026Article
- Primary extranodal marginal zone lymphoma of gastric mucosa-associated lymphoid tissue in children: a case report and review of the literature.Journal of medical case reports · 2026Review
- Primary extranodal marginal zone B-cell lymphoma of the ovary, fallopian tube, and uterus: A rare case report and review of the literature.Gynecologic oncology reports · 2026Article
- Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies.Journal of personalized medicine · 2026Review
- Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy.The American journal of case reports · 2026Article
- Pediatric gastric MALT lymphoma: an antibiotic-treatable lymphoma, a case report and review of the literature.BMC pediatrics · 2026Review
- Article
- EBV-associated histological transformation of marginal zone lymphomas: two case reports and a literature review.Virchows Archiv : an international journal of pathology · 2026Article
- Synchronous mucosa-associated lymphoid tissue lymphoma in a married couple: a case report.Frontiers in oncology · 2026Article
- SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.Clinical lymphoma, myeloma & leukemia · 2026Review
- Secondary cutaneous marginal zone lymphoma arising in association with a Mohs micrographic surgery graft site.JAAD case reports · 2026Article
- Peripheral blood involvement in extra-nodal marginal zone lymphoma.British journal of haematology · 2026Article
- Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma.Journal of hematology · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In 2016 there were an estimated 7,460 newly diagnosed patients with marginal zone lymphoma (MZL) in the US, which comprised 7% of all mature non-Hodgkin lymphomas (NHL). Based on data from the US SEER-18 program from 2001-2017, the age-standardized incidence rate for MZL was 19.6 per 1,000,000 person-years; 9% of MZL cases were splenic MZL (SMZL), 30% nodal MZL (NMZL), and 61% extranodal MZL (EMZL) of mucusa-associated lymphoid tissue (MALT). Incidence rates were slightly higher in men for SMZL and NMZL, but similar for EMZL, and increased steeply with age for all MZL subtypes. The incidence (age-standardized per 1,000,000) of MZL was highest among non-Hispanic whites (20.7), followed by Hispanics of all races (17.6), non-Hispanic blacks (15.4), and Asian/Pacific islanders (15.0). The incidence of MZL increased +1.0% per year in the US from 2001-2017, with increases reported in other countries during this timeframe. The 5-year relative survival rate for MZL in the US was 89.8% and was similar across racial/ethnic groups and by sex; survival rates have been increasing in the US and other countries. Established risk factors for MZL (or MZL subtypes) include family history of NHL, genetic loci in the HLA region,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.